Black Diamond Therapeutics (BDTX) News Today

Wedbush reissued an "outperform" rating and issued a $16.00 target price on shares of Black Diamond Therapeutics in a report on Tuesday.

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - Analysts at HC Wainwright upped their Q3 2024 earnings estimates for Black Diamond Therapeutics in a report released on Wednesday, September 4th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($

HC Wainwright reiterated a "buy" rating and issued a $11.00 price target on shares of Black Diamond Therapeutics in a research note on Wednesday.

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) was the recipient of a significant increase in short interest in the month of August. As of August 15th, there was short interest totalling 6,010,000 shares, an increase of 35.4% from the July 31st total of 4,440,000 shares. Based on an average daily volume of 637,100 shares, the days-to-cover ratio is presently 9.4 days.

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) was the target of a large decline in short interest in the month of July. As of July 31st, there was short interest totalling 4,440,000 shares, a decline of 6.1% from the July 15th total of 4,730,000 shares. Based on an average trading volume of 689,200 shares, the short-interest ratio is currently 6.4 days.

Raymond James started coverage on shares of Black Diamond Therapeutics in a research report on Wednesday. They set an "outperform" rating and a $20.00 price target on the stock.

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) saw a large growth in short interest in July. As of July 15th, there was short interest totalling 4,730,000 shares, a growth of 47.4% from the June 30th total of 3,210,000 shares. Based on an average daily volume of 760,200 shares, the short-interest ratio is currently 6.2 days.

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) saw a large increase in short interest during the month of June. As of June 30th, there was short interest totalling 3,210,000 shares, an increase of 8.4% from the June 15th total of 2,960,000 shares. Based on an average trading volume of 790,500 shares, the short-interest ratio is currently 4.1 days.

Piper Sandler reissued an "overweight" rating and issued a $12.00 target price on shares of Black Diamond Therapeutics in a research note on Wednesday.

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) was the target of a large growth in short interest in the month of May. As of May 31st, there was short interest totalling 2,620,000 shares, a growth of 22.4% from the May 15th total of 2,140,000 shares. Based on an average daily trading volume, of 670,800 shares, the days-to-cover ratio is presently 3.9 days.

Bellevue Group AG grew its holdings in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) by 4.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 8,535,839 shares of the company's stock after buying an addi

HC Wainwright reaffirmed a "buy" rating and set a $11.00 target price on shares of Black Diamond Therapeutics in a report on Friday.

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Black Diamond Therapeutics in a research note issued to investors on Thursday, May 16th. HC Wainwright analyst R. Burns anticipates that

HC Wainwright cut their price target on shares of Black Diamond Therapeutics from $12.00 to $11.00 and set a "buy" rating on the stock in a report on Thursday.

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) was the recipient of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 2,040,000 shares, a growth of 12.7% from the March 15th total of 1,810,000 shares. Based on an average trading volume of 592,500 shares, the short-interest ratio is currently 3.4 days.

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - Analysts at Wedbush issued their Q1 2024 EPS estimates for Black Diamond Therapeutics in a research report issued on Monday, April 8th. Wedbush analyst R. Driscoll anticipates that the company will post earnings of ($0.41) per share f

Wedbush lifted their target price on shares of Black Diamond Therapeutics from $10.00 to $16.00 and gave the stock an "outperform" rating in a research note on Monday.

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - HC Wainwright boosted their Q1 2024 earnings per share estimates for shares of Black Diamond Therapeutics in a note issued to investors on Monday, March 18th. HC Wainwright analyst R. Burns now anticipates that the company will post e

HC Wainwright reiterated a "buy" rating and issued a $12.00 price objective (up previously from $11.00) on shares of Black Diamond Therapeutics in a report on Monday.

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - Equities researchers at Wedbush increased their FY2024 earnings estimates for Black Diamond Therapeutics in a research report issued on Wednesday, March 13th. Wedbush analyst R. Driscoll now expects that the company will earn ($1.76)

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) was the target of a large decrease in short interest in the month of February. As of February 29th, there was short interest totalling 1,780,000 shares, a decrease of 5.3% from the February 14th total of 1,880,000 shares. Based on an average daily volume of 577,500 shares, the days-to-cover ratio is currently 3.1 days.

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) was the target of a large decrease in short interest in February. As of February 15th, there was short interest totalling 1,880,000 shares, a decrease of 21.7% from the January 31st total of 2,400,000 shares. Based on an average daily volume of 537,500 shares, the days-to-cover ratio is currently 3.5 days.

Barclays PLC lifted its stake in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) by 159.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 322,246 shares of the company's stock after purchasing an add

Black Diamond Therapeutics (NASDAQ:BDTX) Trading 2.6% Higher

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) was the recipient of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 3,640,000 shares, a growth of 6.4% from the November 30th total of 3,420,000 shares. Based on an average daily volume of 522,100 shares, the days-to-cover ratio is currently 7.0 days.